SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

About this Trial

An International Phase 3 Randomized, Double-blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Endometriosis

• Status: Enrolling now
• Location: Miami Valley Hospital
• Study type: Interventional
• Ages eligible for study: 18 to 50 years
• Genders eligible for study: Female
• Principal Investigator: Dr. Michael Galloway
• For more information about this study, visit ClinicalTrials.gov: NCT03204331

Contact Us

If you would like information about participating in this study, contact:

Dawn Shields, BS
(937) 208-3689
dashields@premierhealth.com